Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer [0.03%]
根据ESMO分子靶向临床作用评估体系(ESCAT),无特定分子分型子宫内膜癌的基因可操作性分析
L Mastrantoni,F Camarda,C Parrillo et al.
L Mastrantoni et al.
Background: The No Specific Molecular Profile (NSMP) subtype accounts for ∼30%-40% of endometrial cancer (EC), comprising a heterogeneous group of EC. Pa...
Reply letter to comments on: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial [0.03%]
替雷利珠单药或联合治疗实体瘤的Ib期临床研究中针对年龄和性别的有效性和安全性亚组分析:ARMMORPH307III期试验的事后探索性分析回复信
R Fazio,G Randon,F Pietrantonio
R Fazio
Response to: Re: 'Development of a risk score based on clinical-pathological features to predict the presence of germline BRCA1/2 pathogenic variants in ovarian cancer patients' [0.03%]
关于“基于临床病理特征的评分系统预测卵巢癌患者BRCA1/2胚系致病突变存在概率”的评论回复文章
G Innella,G Erini,A De Leo et al.
G Innella et al.
Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study [0.03%]
来自PLATFORM-B研究的转移性结直肠癌(mCRC)患者液体活检-RICEST(LB-RECIST)临床验证结果
V Martelli,J Vidal,J Gibert et al.
V Martelli et al.
Background: Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular re...
Re: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial [0.03%]
关于年龄和性别对雷莫芦单抗联合紫杉醇作为转换维持治疗与一线奥沙利铂为基础的化疗继续治疗的有效性和安全性的影响:ARMANI三期临床试验亚组分析
H Bolek,P Kubilay Tolunay
H Bolek
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial [0.03%]
帕博西尼联合曲妥珠单抗治疗HER2阳性转移性乳腺癌:SOLTI-1303-PATRICIA试验队列A和B的最终总生存期结果
T Pascual,G Villacampa,M Oliveira et al.
T Pascual et al.
Background: The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal growth factor rec...
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice [0.03%]
美国真实世界中CDK4/6抑制剂联合芳香化酶抑制剂治疗HR阳性/HER2阴性转移性乳腺癌的无进展生存期
H S Rugo,R M Layman,F Lynce et al.
H S Rugo et al.
Background: All three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i; palbociclib, ribociclib, and abemaciclib) plus aromatase inhibitor (AI) significantly prolonged progression-free survival (PFS) versus placebo plus AI...
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients [0.03%]
早期发病结直肠癌患者具有独特的分子特征:1209例大规模NGS研究的新发现
A Pretta,V Nasca,F Marmorino et al.
A Pretta et al.
Background: Early-onset colorectal cancer (EO-CRC, ≤50 years of age) exhibits unique clinical and biological characteristics when compared with average-onset CRC (AO-CRC), but its overall molecular profile is still not w...
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib [0.03%]
网络分析鉴定非小细胞肺癌中的NRG1变异对EGFR突变患者一线使用奥希替尼的预后作用
E Vita,A Scala,A Vitale et al.
E Vita et al.
Background: Fusion events involving neuregulin 1 (NRG1), a member of the pan-HER pathway, have been highlighted as a potential therapeutic target; however, little is known about the epidemiological distribution and the pr...